New study aims to personalize chemo for HIV-Linked cancer
NCT ID NCT06480773
First seen Feb 05, 2026 · Last updated Jun 23, 2026 · Updated 26 times
Summary
This study follows 127 people with HIV-related Kaposi sarcoma in Malawi and South Africa who are receiving standard chemotherapy (paclitaxel or bleomycin plus vincristine). Researchers want to understand why some patients respond better than others, looking at factors like gender and virus levels. The goal is to find ways to tailor treatment for better outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Stellenbosch University and Tygerberg Hospital
Cape Town, Stellenbosch, 8000, South Africa
-
UNC Project, Kamuzu Central Hospital
Lilongwe, Malawi
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Paclitaxel or Bleomycin and Vincristine (chemotherapy)
What this could lead to
If successful, this study could help doctors personalize chemotherapy for HIV-related Kaposi sarcoma, potentially improving outcomes and reducing side effects.
What could go wrong
This is an observational study, not testing a new treatment. It may not lead to immediate changes in care, and results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.